A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

Item
http://www.wikidata.org/entity/Q37352435
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerTumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.The role of cell-free DNA in predicting colorectal cancer prognosis.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway.The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Targeting MET in cancer therapy.A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerCell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
P2860

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

Item
http://www.wikidata.org/entity/Q37352435
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
type
label
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
prefLabel
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
A randomized, placebo-controll ...... d first-line systemic therapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
A randomized, placebo-controll ...... ed first-line systemic therapy
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932